Atheroma: links with antiphospholipid antibodies, Hughes syndrome and lupus

被引：37

作者：

Harats, D

George, J

Levy, Y

Khamashta, MA

Hughes, GRV

Shoenfeld, Y ^{[1
]}

机构：

[1] Chaim Sheba Med Ctr, Dept Med B, IL-52621 Tel Hashomer, Israel

[2] Chaim Sheba Med Ctr, Inst Lipid & Atherosclerosis Res, IL-52621 Tel Hashomer, Israel

[3] Chaim Sheba Med Ctr, Autoimmune Dis Res Unit, IL-52621 Tel Hashomer, Israel

[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel

[5] St Thomas Hosp, Rayne Inst, London SE1 7EH, England

来源：

QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS | 1999年 / 92卷 / 01期

关键词：

D O I：

10.1093/qjmed/92.1.57

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Antiphospholipid antibodies (aPL) are found in a variety of autoimmune diseases, and are thought to predispose to arterial and venous thrombosis. These antibodies, when investigated in different assays in vitro, activate endothelial cells and promote uptake of modified LDL to macrophages. These observations suggest that aPL can contribute to atheroma development by targeting some of the sequential steps that constitute early atherogenesis. If substantiated by large-scale clinical trials, the pro-atherogenic properties of aPL may merit screening and intervention programs in selected populations.

引用

页码：57 / 59

页数：3

共 18 条

[1]

CUADRADO MJ, 1997, ACR M WASH DC

[2] Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with β2-glycoprotein I [J].